As multinational pharma seek new strategies to ensure continued growth, diversification into new markets remains a popular approach. With some of the most populous and rapidly developing markets in the world, Asia Pacific has been attracting the attention of the international pharmaceutical industry, leading to significant partnership activity among Asia Pacific-based companies in recent years.
Features and benefits
- Overview of drivers, resistors and trends within the Asia Pacific deals and alliances landscape.
- Summary of geographic licensing and partnering activity on a regional and country-specific basis.
- Analysis of the types of partnerships and healthcare sectors targeted.
- Examination of transaction values and leading dealmakers.
Drivers of licensing and alliances in APAC include low cost R&D, and improving R&D capabilities and business operating environments. The acquisition of biologics is increasingly commonplace, and more Big Pharma companies are venturing into the generics space—a strength in emerging Asian markets—to help offset slowing sales in the developed markets.
Nearly all deals reported in the APAC region between Q3 2010 and Q2 2011 involved companies from one of five key markets—Japan, India, Australia, South Korea and China.
India has become the go-to destination to access generics, but Japanese companies dominate the licensing, research, and marketing deal landscape due to the size and maturity of the Japanese market. Over three times as many deals involved Japan-based companies compared to other Asia Pacific countries from Q3 2010 to Q2 2011.
Your key questions answered
- Which are the most highly valued pharmaceutical sectors for licensors, and which companies have been the most active in APAC in recent years?
- Which APAC markets have been most frequently targeted for partnerships, and which have attracted the attention of Big Pharma?